Note: Descriptions are shown in the official language in which they were submitted.
CA 02552442 2003-12-17
-1a
Compos'rtior~s and Delivery Methods for the Treatment of Wrlnttles,
Eine Lines and Hyperhidrosis
FIELD C.~IL THE INVENTION
[0001 j The present invention generally relates to compositions and
methods for shin and personal care involving components as active agents
that exert their effects at the neuromuscular junction of muscle and nerve
cells and tissue. Such compositions and methods are particularly suitable
.or the treatment and prevention of wrinkles, tine lines end hyperhidrosis of
skin. Mare particularly, the present invention relates to compositions
including giant or fruit constituents which can work at the level of the
muscle
and affect muscle relaxation as a consequence of the use, preferably topical
use, of these compositions. Such constituents include, far example,
limonaids, e.g., plant alkaloids; from the Maliaecae family, suds as
toosendanin from Melia Toosendan Sieb. Et. Zucc. (the Chinaberry treej
and azadirachtin from Melia Azadirachta (the Neem tree). The invention
further relates to methods of delivery for such campos'rtlons so as to allow
the active components to more readily reach the muscle layer and
preferably function at the level of the neuromuscular junction of faaal
muscles, more preferably facial expression muscles, to treat, including
preventing, reducing, ameliorating, andlor eliminating, signs of
dermatolagical aging, for example, wrinkles, fine lines, folds and furrows in
the skin; to treat, prevent, or reduce hyperhidrnsis; andlor to improve the
aesthetic appearance of the skin.
[0002] A number of treatments and compositions for topical
appiica~on are promoted in the art for mitigating dermatological cor!ditions
of
the skin which frequently are associated with natural or snvironrnental
causes, such as the process of aging (i.e., intrinsic agingj; exposure to the
sun, or the resulting ultraviolet radiation therefrom (i.e., extrinsic aging),
and
CA 02552442 2003-12-17
-2-
the like. Other factors, such as improper care and/or diet, stress,
nutritional
deficiencies, repeated facial movement and' genetic predisposition also
contribute to the development of adverse skin conditions, such as fine fines,
frown fines, folds, furrows and wrinkles.
[0003] Popular culture and trends, the fashion industry, and many
arms of the current media promote and encourage a youthful appearance
that reflects skin, particularly facial skin, which is free of wrinkles, fine
fines
and the tike. In today's world, both women and men desire to maintain a
youthful, wrinkle-free appearance for as Long as possible and consequently
seek to prevent, reduce, improve, or eliminate the signs of aging (and/or sun
exposure) which reveal themselves in the forms of fine lines, furrows, and
wrinkles, for example. The products commonly available to date for this
purpose typically contain agents that act on the skirt by merely moisturizing;
promoting cell growth, swelling the extraceltutar matrix (by, for example,
increasing or promoting the synthesis of collagen, elastin or
glycosaminoglycans) which comprises skin. Calcium channel inhibitory
agents that act on calcium channels of subcutaneous muscle and/or nerve
tissue have also been described as components of compositions to relax
and/or decontract cutaneous andlor subcutaneous tissue whose contraction
is associated with wrinkle formation (U.S. Patent No. 6,344,461 B1 to L..
Breton et at.).
[0004] Compositions containing active agents and ingredients for use
in personal care products to affect, prevent, and/or reduce hyperhidrosis,
such as antiperspirants and deodorants, are also widely employed in the
general population. Such compositions are provided to reduce and prevent
perspiration and body malodor associated with human perspiration and
sweating, particularly underarm malodor, and ideally should contain
constituents that are effective in the treatment of sweating following topical
application to the skin. While antiperspirants combat auxiliary body
CA 02552442 2003-12-17
-3-
malodors by inhibiting perspiration through, for example, the action of
astringent salts such as aluminum and zirconium salts, deodorants
neutralize objectionable odors resulting from the degradation of the
components of sweat which are attacked by chemicals and microbes,
thereby producing foul-smelling fatty acids.
[0003 By the regular use of antiperspirants or deodorants, a
considerable number of users have experienced pain and/or irritation in the
sensitive skin or body surface to which the antiperspirant or deodorant is
applied, due to the active salts in these compositions, as well as to skin
sensitivity. As is appreaated by the practitioner, deodorants are generally
less irritating to the skin than antiperspirants because deodorants do not
inhibit sweat, but rather neutralize the degradation products of sweat
Despite this, however, deodorants can also be irritating to sensitive skin,
particularly for those whose skin is compromised in certain areas (e.g., the
underarm area) as a result of shaving. Also, deodorants are difficult to use
in other sweat prone areas (e.g., feet, palms, groin). In view of the
widespread use of such personal care products, effective antiperspirant and
deodorant compositions are desired to inhibit, prevent, or reduce
perspiration and body matodor with less irritafion to the body and stein of
the
user.
[0006 Many of the compositions described for various topical
treatments of the skin include components, such as alpha-hydroxyacids
("AHAs"), that may provide only supe~ciat effectiveness, or that may cause
adverse side effects to the user's skin, for example, irritation. Indeed, some
commonly used compositions and methods for reduang fine tines and/or
wrinkles contain AHAs, such as gtycolic acid, lactic acid, tartaric acid and
citric acid, and salts thereof, or they contain tretinoin, also known as alt-
trans
retinoic acid or retinot (Vitamin A), or ascorbic acid (Vitamin C), all of
which,
without further mitigation, can induce the above-mentioned disadvantageous
CA 02552442 2003-12-17
-4-
effects, often due to a lowering of the pH of the skin, among other factors.
To provide maximum effectiveness and to avoid or prevent the foregoing
types of adverse reactions, new and alternative components of compositions
and formulations for the treatment and care of the skin are desired,
[0007) Human skin comprises two major compartments: a superfiicial
outer compartment; the epidermis, and a deeper compartment, the dermis.
The outermost epidermal skin layers typically provide a certain degree of
protection to the body, although fine lines and wrinkles can be readily
visualized in this portion of the skin. The epidermis and dermis bear the
brunt of harmful effects of photodamage. The natural human epidermis
functions to provide the essential protectant role of the skin in the human
body. The dermis, which provides a solid and nutritional support to the
epidermis, comprises mainly fibrobtasts and an extracellular matrix
composed primarily of a substance that includes ootlagen, elastin and
glycosaminoglycans ("GAGs"). In addition, the dermis contains leukocytes,
mast cells, tissue macrophages, blood vessels, muscle dells and nerve
ftbers.
[0008] The dermal muscles of the face are controlled by motor nerve
afferences of the facial nerve. The interlobular septa of the hypoderm
contain within them fibers that institute a striated muscle tissue, i:e., the
panniculus camosus. It is known that a subpoputation of dermal fcbrobtasfs,
called myofibrobtasts, has contractile characteristics similar to those of
muscle cells and tissue.
[0009] Botutinurn toxin, (also known by the trade name, Botox'~,
Allergen, Irvine, Catif.), is currently in vogue for treating wrinkles and
trne
lines, but was initially used to treat spasms, This toxin acts on states of
muscular spasticity by specifically inhibiting neurotransmission in nerve
cells, thereby causing contracted muscles to relax (e.g., A. Blitzer et al.,
1993, Arch. Otolaryngol. Head Neck Surg., 119:11&122; U.S. Patent No.
CA 02552442 2003-12-17
-5-
6,344,461 81 to L. Breton et al.). Botutinum toxin also can act on wrinkles of
the glabella (wrinkles between the eyebrows) when injected subcutaneously.
(See, J.D. Carruthers, 1992, J. Dermatol. Surg. Oncol., 18:17-21; U.S.
Patent No. 6,344,461 B1 to L. Breton et al.). However, the full extent of
adverse effects related to long-term use of botuiinum toxin and products or
treatments containing this material are still not well established. Botulinum
toxin treatment has been associated with a number of side effects including,
transient fatigue, dysphagia, neck weakness, hoarseness, and localized
pain. 1n addition, many patients who preliminarily respond to botulinum toxin
subsequently become non-responsive to treatment. (See, e.g., published
U.S. Patent Application No. US2002100812914 to Hawrot).
[0010 New ingredients for use as effective, active agents in
compositions and formulations for application, preferably topical application,
to the skin are advantageous to the industry and the consumer for a variety
of uses in the areas of skin care treatment and therapy, and personat use
products.
[0011 J Plant extracts and substances serving a variety of diverse
purposes include limonoid constituents of the Maliaecae and Rutaceae
families. Limonoids are a group of chemically related triterpene derivatives
which are among the bitter principles found in citrus fruits such as lemons,
lime, orange and grapefruit. They are also present as glucose derivatives in
mature fruit tissues and seeds, and are one of the major secondary
metabolites present in citrus. More specific examples of such plant
materials include the plant alkaloids toosendan (from Melia Toosendan Sieb.
Et. Zucc), (i.e., Chinaberry) and azadirachtin (from Melia Azadirachta (i.e.,
Neem). Limonoids have been known to have insecticidal properties (e.g.,
U.S. Patent No. 6,372,239 to Wu et al.; U.S. Patent No. 5,885,600 to M.
Blum et al.), as weft as anti-neoplastic and anti-carcinogenic effects in
laboratory animals (e.g., U.S. Patent No. 5,370,873 to t.J. Udeinya; U.S.
CA 02552442 2003-12-17
-6-
Patent Nos. 6,239,114 and 6,251,400 to N. Guthrie et a!.). The furan moiety
attached to the D-ring is specifically responsible for detoxifying the
chemical
carcinogen glutathione-S-transferase enzyme system (Lam et al., 1994,
Food Technology, 48:104-108).
[0012] Citrus fruit tissues~and the byproducts of juice processing,
such as peels and molasses ace sources of limonoid gfucosides and citrus
seeds contain high concentrations of both limonoid agtycones and
glucosides. Limonoid aglycones in the fruit tissues gradually disappear
during the (ate stages of fruit growth and maturation. Thirty eight limonoid
aglycones have been isolated from citrus. The limonoids are present in
three different forms, namely, the dilactone is present as the open D-ring
form (monolactone), the iimonoate A-ring lact~e and the glucoside form
(See, e.g., U.S. Patent No. 6,239;114 to N. Guthrie et at.). Only the
monolactones and glucasides are present in fru~ tissues. (Hasegawa S. et
al., 1994, In: Food Phytochemicats for Cancer Prevention t; Eds M-T.
Huang et aI, American Chemical Society, 198-207).
[0013] Procedures for the extraction and isolation of both agiycones
and glucosides have been established to obtain concentrated sources of
various limonoids (Lam, L,K.T. et al., 1994, !n: Food Phytochemicals for
Cancer Prevention, Eds. M. Huang, T. Osawa, C. Ho and R. T. Rosen, ACS
Symposium Series 546, p 209).
[0014] Safe, effective and new components of compositions to treat,
prevent, reduce, inhibit, and/or improve the dermatological signs of aging, as
well as hyperhidrosis, would be advantageous for the formulation of
treatments and products for the skin. As described herein, novel 'and
beneficial methods and compositions, as well as their mode of action, for the
treatment of wrinktes and the like, as well as for personal care products for
the skin, are provided by the present invention.
CA 02552442 2003-12-17
-7-
SUMMARY OF THE INVENTION
[0015] The present invention provides compositions and methods
comprising plant-derived constituents newly found to be effective to treat,
including prevent, reduce, ameliorate, andlor eliminate, signs and results of
dermatologicat aging of skin, espeaally wrinkles and fine lines, and/or to
improve the aesthetic appearance of skin. Further these constituents are
provided for use in compositions and methc?ds to treat, including prevent,
ameliorate, and/or reduce, hyperhidrosis (or sweating or perspiration) and its
associated effects, such as malodor. More specifically, the active
constituents (also refen~ed to as active agents, components, ingredients,
reagents, or compounds herein)~are Iimonoids, obtained from plants and the
fike, of the Mafiaecae family. Nonlimiting examples of timonoids for use~in
accordance with this invention include the plant alkaloids toosendanin from
Metta Toosendan Sieb. Et Zucc (more commonly known as the Chinaberry
tree, Ku Lian Pi extract, or Melia azedarach); and azadirachtin from Melia
Azadirachta (more commonly known as the Neem tree or Azacdiracta
indica). These plant materials have been newly found to provide treatment
for wrinkles, fine lines and. other signs of dermatologicat aging (i.e.,
intrinsic
aging) or sunlight exposure of the slan (i.e., extrinsic aging), as well for
use
in the treatment of hypefiidrosis, by virtue of their effect at the
neuromuscular junction (NMJ) of muscle and nerve cells and tissue; arid at
the ftbers of the sweat glands to inhibit acetylcholine release, e.g., at the
NMJ, thereby relaxing or decontracting muscles, e.g., facial expression
muscles.
[0016] It is to be understood that, as used herein, the terms treating
and treatment include and encompass preventing, reduang, ameliorating,
improving, alleviating, andlor eliminating the dermatological effects of aging
and sun exposure, with particular regard to wrinkles, fine lines, folds,
furrows, creases of the skin, and the tike. The present invention further
CA 02552442 2003-12-17
_$_
encompasses the treatment, as defined above, of umarionette" tines that run
on either side of the mouth, as well as lines on the forehead, and the
perpendicular fines between the brows. The present compositions and
methods are also suitable for use in treating, as defined above,
dermatological conditions of the skin in numerous areas of the body,
including, without limitation, the face, forehead, neck, arms, hands, legs,
knees, feet, chest, back, groin, buttocks, and the Like.
[00171 It is another aspect of the present invention to provide
compositions, formulations and methods containing materials newly
determined to be useful in the treatment of wrinkles, fine tines, folds,
furrows
and other signs of aging skin, in addition to treating, preventing or reducing
hyperhidrosis. These materials exert their effectiveness according to this
invention by preferably working at the neuromuscular junctions (NMJ), such
as in the muscle and nerve cell or tissue layer of a site of application,
e.g.,
skin of the face, neck, arms, feet, or hands, or in the demlal layer of the
skin
where sweat glands are located. More specfically, the limonoid constituents
(i.e., chemical actives, such as toosendanin or azadirachtin, or a
combination thereof) block or inhibit the release of acetylcholine at the NMJ
of skeletal muscle, which, in tum, results in the relaxation or decontractson
of
contracted muscles. Contracted muscles are associated with the fom~a#ion
of fne fines, wrinkling and the like.
j0018~ According to the present invention the materials, in general,
comprise plant alkaloids, or limonoids of the Matiaecae family. More
specifically, the Itmonoids comprise toosendanin and azadirachtin, which
were not previously known to inhibit acetytcholine release in NMJ of skeletal
muscles, thereby relaxing the facial expression muscles, for example, to
treat, prevent, reduce, ameliorate, and/or eliminate aesthetically displeasing
wrinkles, frown lines, fine Lines, folds, furrows, or neck bands, etc. that
can
arise from aging, prolonged sun exposure of the skin, ultraviolet radiation
CA 02552442 2003-12-17
_g_
associated with sun or photoexposure, or in particular, hyperactive facial
expression muscles.
[0019] In addition, because it is understood that the contraction or
hypercontraction of certain muscles, particularly facial muscles, is related
to
the appearance of wrinkles, fine lines, etc., the relaxation of such muscles,
and/or the control or modulation of the contraction of such muscles, by the
newly-determined action of the limonoids as disclosed herein can serve a
pivotal function in the treatment, prevention, reduction, amelioration, or
elimination of wrinkles, fine lines and the like.
[0020] In accordance with this invention the limonoid materials
comprise compositions which include, without limitation, topicahy applied
sunscreens, anti-oxidants, anti-inflammatories, cosmetics, inducting
makeups, anti-aging formulations, e.g, cxeams for fine lines andlor wrinkles,
topicals, skin permeants antiperspirants, deodorants and the like. Also in
accordance with this invention, ingredients, components, or compounds that
are formulated in such compositions in a variety of product forms, e.g.,
transdermals, such as patches, and the like, are encompassed, particularly
for topical administration.
j0021 ] Another aspect of the present invention. provides the
compositions comprising the limonoid materials preferably for topical
administration without inducing significant irr<ttation. Further, such
compositions are preferably delivered by, but not limited to, the use of
targeted delivery systems, for example, liposomes, micraspheres,
transdermal patches, and the tike, so that the actives can more readily reach
and affect the muscle layer of the area of application, e.g., face or neck, or
the dennai layer of the skin, where sweat glands are located, e.g.,
underarm, foot, hand, etc. Compositions comprising iirnonoid constituents,
including liposome formulations, can be administered by direct injec~on
subcutaneously, intradermally, or through iontophoresis, to deposit the
CA 02552442 2003-12-17
active agents at the sites requiring muscle relaxation or decontraction.
[0022] In another of its aspects, the present invention provides
limonoid-containing compositions and methods thereof which can improve
the aesthetic appearance of the skin by treating, including preventing,
ameliorating and/or reducing at least one of the following: dermatologicaf
aging, especially chronological, actinic or hormonal aging. The
improvement preferably results following topical application of a product or
formulation containing one or more of the limonoid constituents as described
herein.
[0023] Another aspect of this invention provides a method of
reducing, preventing, treating, or ameliorating wrinkles, fine lines, creases,
frown lines, or other signs of dermatological aging, or photoexposure of skin,
comprising: applying a composition comprising an acetytcfwline antagonist
at a site comprising a neuromuscular junction (NMJ} in an amount effective
to reduce or block acetylcholine release at the neuromuscular junction
(NMJ), wherein the reduction or block of acetylcholine release at the
neuromuscular junction (NMJ) concomitantly reduces or blocks muscle cell
or tissue contraction (or contractility}, thereby treating, preventing,
reducing,
ameliorating, or eliminating the formation of wrinkles, fine lines, creases;
folds, frown lines, or other signs of demzatotogical aging, hyperactive facial
expression muscles, or photoexposure. Preferably, the acefylcholine
antagonist is a limonoid constituent, more preferably a limonoid constituent
of the Maliaecae family, and most preferably, toosendanin or azadirachtin.
[.Q024] A further aspect of this invention provides a method of
reducing, preventing, treating, or ameliorating hypefiidrosis or perspiration,
particularly, excessive perspiration, comprising: applying'a composition
comprising an acetylcholine antagonist at a site comprising a neuromuscular
junction (NMJ), preferably in the fibers of a sweat gland, in an amount
effective to reduce or block acetylcholine release at the neuromuscular
CA 02552442 2003-12-17
-11-
junction (NMJ), wherein the reduction or block of acetylcholine release at the
neuromuscular junction (NMJ) concomitantly reduces or blocks contraction
(or contractility) of cells in the dermis associated with the sweat gland,
thereby reducing, preventing, treating, or ameliorating hypefiidrosis or
perspiration. Preferably, the acetytcholine antagonist is a limonoid
constituent, more preferably a limonoid constituent of the Maliaecae family,
and most preferably, the Iimonoids toosendanin or azadirachtin.
[0025] Further aspects, features and advantages of the present
invention will be better appreciated upon a reading of the detailed
description of the invention.
DESCRIPTION OF THE INVENTION
[0026) The present invention provides novel compositions and
methods comprising components newly found to be effective to treat,
including prevent, reduce, ameliorate, inhibit, alleviate, and/or eliminate
signs and results relating to the dermatological aging of skin due to
chronological and/or hormonal aging, or due or to photoexposure (e.g., to
the sun, or ultraviolet radiation) of skin, espeaally wrinkles, creases,
furrows, folds and fine lines; and/or to improve the aesthetic appearance of
skin. These components are further provided for use in compositions and
methods to treat, including prevent, ameliorate, inhibit and/or reduce,
hyperhidrosis (sweating or perspiration) and its associated effects, such as
malodor and unaesthetic appearance. .
[00271 More specifically, the components (also referred to as active
agents, constituents, ingredients, reagents, substances, or compounds
herein} of this invention are limonoids, obtained from plants and the tike,
preferably of the Maliaecae family. Noniimiting examples of timonoids for
use in accordance with this invention include the plant alkaloids toosendanin
from Metia Toosendan Sieb. Et. Zucc (more commonly known as the
Chinaberry tree or Melia azedarach); and azadirachtin from Melia
CA 02552442 2003-12-17
-12-
Azadirachta (more commonly known as the Neem tree or Azacdiracta
indica). Azadirachtin is a limonoid of the tetranortriterpenoid type. These
plant materials have been newly determined to be effective constituents in
compositions and methods for treating, preventing, reducing; inhibiting,
improving and/or eliminating wrinkles, fine lines, creases, folds, fun-ows,
and
other signs of dermatologicat aging due to chronological andlor hormonal
aging, or due to sunlight exposure of the skin, as welt for use in the
treatment of hyperhidrosis.
[0028] According to the present invention, yet without wishing to be
bound by theory, the limonoid constituents exert their effects by their
ability
to inhibit, block, reduce, or prevent the release of acetylcholine at the
neuromuscular junction (NMJ) of skeletal muscle cells and tissue, thereby
relaxing muscles, for example, muscles assodated with fadal movement or
expressions, or the fibers of the sweat glands. Both nerve and muscle cells
(skeletal muscle cells) are electrically excitable and the junctions between
these types of cells are known as NMJ. It has been known for many years
that the stimulation of a motor nerve innervating a skeletal muscle also
causes the release of acetylcholine and that acetylcholine; in tum,
stimulates the skeletal muscle to contract. Thus, acetylcholine has been
identified as the neurotransmitter at the neuromuscular junction. (see, e.g.,
B. Alberts et al., 1989, Molecular Biology of the Cell, 2"d Ed., Chapter 19;
The Nervous System, Garland Publishing, Inc., NY., pp. 1075 et seq.).
Provided by the present invention are Iimonoid constituents which are newly
described herein to inhibit, reduce, block, or prevent the release of
acetyicholine at the NMJ of the skeletal muscle and thus relax the muscles,
preferably those associated with facial expression or movement, particularly
when employed in the compositions and methods of the invention. By also
being able to inhibit aceiyichotine release in the fbers of the sweat glands,
compositions and methods comprising the limonoid constituents as
described herein can reduce, treat, and/or prevent excessive sweating or
CA 02552442 2003-12-17
-13-
perspiration.
[0029] The ability of the limonoid constituents to inhibit acetylcholine
release by muscle cells results in a modulation of motor contraction so as to
relax the muscle fibers in cutaneous or subcutaneous muscle and/or nerve
tissue, thereby attenuating wrinkles, as well as fine lines, folds, furrows,
and
the tike. By relaxing or preventing the contraction or hypercontraction of the
cutaneous or subcutaneous muscle cells of areas such as the face, or
hands, feet, etc., the Iimonoids and compositions containing limonoids can
effectively smooth out the Landscape of the skin in those areas where
muscle contraction is involved in the formation of wrinkles and the like.
Thus, if muscle cell contractility is associated with the formation of
wrinkles,
fine lines, etc., the relaxation or decontraction of the contractility of
cutaneous or subcutaneous musde tissue by the timonoid actives in the
compositions of this invention can serve to Loosen or slacken the contracting
muscle tissue and alleviate, reduce, ameliorate, inhibit, or eradicate the
wrinkles, fine lines, etc. Contraction of cutaneous or subcutaneous muscle
cells or tissue of skin can elicit wrinkling, fine lines, and the like, which
constitute at feast some of the visible dermatologicai effects of aging due to
chronological and/or hormonal aging, and/or due to photoexposure, as
described herein.
[0030] Thus, in one of its embodiments, the present invention
encompasses compositions, formulations and methods containing
components, preferably, limonoid constituents, newly determined to be
useful in the treatment of wrinkles, fine fines, folds, furrows and other
signs
of aging and/or photoexposure of skin, in addition to treating, preventing or
reducing hypefiidrosis. Skin in a variety of areas of the body is amenable
for treatment andlor receipt of the compositions of the present invention,
including the face, forehead, neck, amps, legs, hands, feet, torso (chest),
back, and the tike.
CA 02552442 2003-12-17
-14-
[0031 ] The plant-derived materials exert their effectiveness according
to this invention by preferably working at the neuromuscular junctions
(NMJ), such as in and around muscle and nerve cells and tissue at a site of
application, e.g., the skin of face, neck, arms, feet, hands, or chest, or in
the
dermis layer of the skin where sweat glands are located. According to this
invention, the materials, in general, comprise limonoids, which are plant
alkaloids, of the Mafiaecae family. More specfically, the limonoids comprise
toosendanin and azadirachtin, which are plant alkaloids. Prior to the present
invention, these materials were not previously known or recognized to inhibit
acetylcholine release at NMJ of skeletal muscles, thereby relaxing muscles
associated with aesthetically displeasing wrinkles, frown lines, fine lines,
folds, furrows, ceases, neck bands, and the tike, that can arise from aging
due to chronological andlor hormonal aging, prolonged or overexposure of
the skin to the sun, ultraviolet radiation assoaated with phofioexposure; or
over-exercised expression muscles.
[Q032j In general, for the purposes of the present invention, a
substance, such as a limonoid constituent of the described compositions, is
recognized as being a muscle relaxant when it elicits a relaxation effect on
contracted muscle cells or orr tissue, such as cutaneous or subcutaneous
muscle tissue, and/or exhibits an inhibitory effect on acetylcholine release
at
the NMJ. Contracted musde ~tls or tissue is associated with formation of
wrinkles, frne lines, etc. Relaxation or decontraction of contracted muscle,
such as by the action of limonoids to inhibit or block acetylcholine release
at
the NMJ, serves to smooth out the landscape, or microrelief, of the skin,
thereby effecting the prevention, amelioration, reductiort, and/or eradication
of wrinkling and fine line, etc. formation caused by contracted muscle tissue
in skin.
[0033] . For use in the compositions of this invention, the limonoid plant
alkaloids can be chemically synthesized. Alternatively, these plant alkaloids
CA 02552442 2003-12-17
- 15-
may be extracted from plants. When extracted, they may be in a pure form,
a semi-purified form, or may be a component of an unpurified plant extract.
For example, toosendanin may be extracted from the plants Melia
toosendan Sieb. et Zucc. and Me(ia azedarach t_. Azadirachtin may be
extracted from the plant Melia azedarach L. As a result of some structural
similarity, azadirachtin may mimic the function of toosendanin. Further, the
compositions of the present invention can comprise a combination of plant
alkaloids that are formulated to achieve the desired effects to combat
wrinkles, and the tike, and hyperhidrosis. The alkaloids as active ingredients
may exert their effects via multiple mechanisms and signal transduction
pathways.
[0034] The limonoid plant alkaloids contained in the compositions of
the present invention can be chemically synthesized at industrial scale in
large amounts. Alternatively, the alkaloids may be extracted from natural
raw materials from plants: Any and alt methods of preparation may be used,
including- the use of-cultured plant seed cells, as disclosed in commonly
owned patent apptidation U.S. publication ;number 2003-009T659.
The level of extraction and the degree of
purity of the alkaloid may vary. For example, unpurifced plant ex>zacts may
be employed in the present invention_ Depending on the solut~ility of the
particular plant alkaloid in water or in organic solvent, the extraction
process
for each alkaloid may differ. Two methods for extracting the alkaloids from
raw plant materials include organic solvent extraction, and aqueous-organic
solvent extraction, as described in U.S. Patent No. 6,372,239 to Wu et at:
The organic extraction method involves a step of continuous washing and
extracting the plant material against a stream of organic solvent. l=xamples
of organic solvents include, but are not limited to methanol, ethanol,
dichloromethane, chloroform, xylene, and petroleum ether. Alternatively, the
alkaloid can be partially purified or completety purified. Chemical synthesis
of the alkaloid obviates the need for extraction and purification.
CA 02552442 2003-12-17
-16-
[0035] In accordance with this invention, the limonoid constituents
comprise compositions which include, without limitation, topically applied
formulations, anti-oxidants, anti-inflammatories, sunscreens, cosmetics,
including make-ups, anti-aging formulations, e.g., creams for fine lines
and/or wrinkles, topicats, skin penetration enhancers, antiperspirants,
deodorants, and the tike. Also in accordance with this invention, the
timonoid constituents and additional ingredients cor»prising such
compositions can be formulated in a variety of product formsf- Preferably,
the compositions are prepared in targeted delivery systems, eg.,
transdermals, such as patches, and the like, particularly for topical
administration.
j0036~ The present invention encompasses compositions"comprising
one or more limonoid constituents; preferably in a pha'rtnaoeut~il~
acceptable ~sn~etic or dermatological formulation which is suitable for
contact with living animal tissue, ~nduding~hutnan tissc~e, and fair topical
administration, with virtually no adverse physiological effect, e;g:,
irritation,
to the user. Thus, the inventive oomposfions-are espeaatty sut~abte fot
sensitive skin_
[0037 Compositions embraced by this invention-can be provided-in
any cosrneticatlyandlor dermatotogicalty suitable fio; preferably as a - .
lotion, gel, cream,, or incorporated into a trapsdermai patch; .and also in an
ointment or oil base, as weft as in a spcayabte liquid form. Other suitable
cosmetic product forms for the compositions of this invention i~tcfude, for
example, an emulsion, a mousse, a lip balm, ~alip gloss, a lotion, a mask, an
ointment, a pomade, a solution, a serum, a spray; of a towelette. In
addition, the compositions contemplated by this invenfiion. can include one.
or
more compatible cosmeticatly acceptable adjuvarwts eoirtvrr~onty used and
known by the skilled practfioner, such as colorants; fragrances; emzyilients,
humectants, preservatives, vitamins, chetators, thickeners, and the tike, as
CA 02552442 2003-12-17
-17-
well as other botanicals such as aloe, chamomile, and the tike, and as
further described below. The compositions are preferably applied topically
once or twice daily. The daily application can be for periods of up to two
weeks, four weeks, or more.
[0038 In one embodiment encompassing sunscreen formulations, the
compositions comprising timonoid constituents can further include, without
limitation, ingredients such as avobenzone, cinnamic acid derivatives (e.g.,
octylmethoxycinnamate), octyl salicylate, oxybenzone, titanium oxide, zinc
oxide and mixtures or combinations thereof. Such formulations can also
preferably include an alpha hydroxy acid, an oxa acid, an oxa diacid, and
mixtures or combinations thereof.
[0039 The compositions of this invention can also be formulated into
liposomes which can comprise other additives or substances, and/or which
can be modfied to more specifically reach or remain at a site following
administration. Alternatively, the limonoid-containing compositions can be
injected subcutaneously (s.c.) or intradermally (i.d.) at a site in need of
wrinkle, Fine line, etc. reduction, improvement, prevention, andlor
elimination, resulting from inhibition of acetylcholine release at the NMJ and
concomitant relaxation of contracted muscle.
[00401 Pharmaceutical or physiologically acceptable compositions
suitable for use in the present invention include compositions in which the
active constituents, ingredients, or materials are contained in an amount
effective to achieve the intended purpose. By way of example, in the
present compositions, a limonoid constituent is present in an amount of from
about 0.0001 wt% to about 10 wt%, based on the total weight of the
composition. More preferably, the present compositions include one or
more limonoid constituents in an amount from about 0.000 wt% to about 5
wt%. Most preferably, the present compositions include one or more
limonoid constituents in an amount from about 0.001 wt% to about 1 wt% c~f ;
CA 02552442 2003-12-17
-18-
the total composition.
[0041 ] The determination of an effective dose or amount is well within
the capability of those skilled in the art. A therapeutically effective dose
refers to that amount of active ingredient, for example, a limonoid
constituent identified in accordance with the present invention, which, for
instance, treats, prevents, ameliorates, reduces, or eliminates the condition,
more specifically, wrinkles, fine lines, creases, and the like. The
practitioner,
who will consider the factors related to the individual requiring treatment,
wilt
determine the exact dosage. Dosage and administration are adjusted to
provide sufficientJevels of the active constituent or to maintain the desinrd
effect. Factors which are typically considered include the severity of the
individual's particular need, general health of the patient, age, weight, and
gender of the individual, diet, time and frequency of administration; drug
combination(s), reaction sensitivities, and toierancelresponse to treatment.
As a general guide, long-acting pharmaceutical compositions can be
administered once daily, every 2 to 4 days, every week, or once every two
weeks, depending on half life and clearance rate of the particular
formulation. Variations in these dosage levels can be adjusted using
standard empirical routines for optimizafion, as is well understood in the
art.
Guidance as to particular dosages and methods of delivery is provided in
the literature and is generally available to practitioners in the art. Those
skilled in the art will employ different formulations depending upon the
nature, e.g., structure, composition, of the active limonoid constituent.
j0042] With particular regard to fimonoids as anti-hyperhidrosis
agents in anti-perspirant or deodorant composifions and formulations for
personal use, such products embrace a wide variety of dosage forms, such
as stictcs, gels, roll-ons, aerosols, and creams. These dosage forms
generally contain a solution of the active ingredient in a solvent, usually
non-
aqueous, or in a multiphasic dispersion or emulsion in which a solution of
CA 02552442 2003-12-17
_ q9 _
the active ingredient is dispersed in some continuous phase or in which the
solubilized active ingredient constitutes the continuous phase. To produce
natural-looking, products that leave minimal visible residue on the skin;
clear
and translucent antiperspirants, e.g., sticks or gels, can be utilized. Clear
or
translucent gelled antiperspirant sticks'which are substantially anhydrous,
typically contain the active material, a stabilizer as an essential component,
and are gelled in a gelling agent, such as dibenzylidene monosorbifot acetal
(see, e.g., U.S. Patent No. 5,376,363 to A.J. Benfatto et al.). Other
compositions provide antiperspirant active materials in geltants of different
types, such as polyamide gelling agent (e.g., U.S. Patent No. 5,500,209 to
M.S. Mendolia et at.).
[0043] The compositions of the present invention yield improvements
to the aesthetic appearance of the skin by treating at least one of the
following: signs of dermatologicat aging, especially chronological, actinic or
hormonal aging, or signs of extrinsic aging, such as sun exposure. In
particular, improvements to the aesthetic appearance of skin include at feast
one of the following: makes facial lines appear tess noticeable, maker faaal
lines and/or wrinkles feel plumped, improves appearance of suborbital tines
andlor periorbital lines, improves appearance of crow's feet, reduces fcsr
diminishes the appearance of wrinkles, particularly faaal wrinkles o~'
cheeks, forehead (e.g., perpendicular wrinkles between eyes, horizontal
wrinkles above the eyes), and/or around the mouth, (e.g., marionette tines),
and particularly deep wrinkles, folds, or creases, improves skin suppleness;
reduces and/or eliminates fine andlor deep lines, folds and creases, and
smoothes skin, e.g., to the extent that it reduces wrinkling/fines.
[0044] Embraced by the present invention are transdermal modes of
delivery, such as patches and the like, with or without a suitable skin
penetration enhancer. The methods and compositions embodied by the
invention provide a means by which the one or more limonoid constituents
CA 02552442 2003-12-17
-20-
can be effectively administered in a transdermal system. Frequently,
compounds having poor topical absorption, or which are required at high
dosage levels, are delivered transdermalty. Accordingly, a transdermal
means of delivering a composition or formulation (often with a skin
penetration, enhancer composition) to the skin is that of the transdermal
patch or a similar device as known and described in the art Examples of
such devices are disclosed in U.S. Patent Nos. 5,146,846, 5,223,262,
4,820,724, 4,379,454. and 4,956,'!71; such descriptions are not meant to be
limiting. The transdermal mode of storing and delivering the compositions
onto the skin and forming the active composition is convenient and well
suited for the purposes of an embodiment of the present invention.
Preferably, when a topical patch is used, the patch is applied to the desired
area for extended period of time. Preferably, the extended period of time is
greater than one hour; more preferably, the extended period of time is
overnight, e.g., when the user is sleeping.
[0045 A particular embodiment of the present invention is directed to
the delivery of the described compositions by the use of targeted delivery
systems, for example, tiposomes, microspheres (see, e.g-., U.S. Patent No.
5,770,222 to Unger et ai.); transdermat patches, and the like, so that the
Iimonoid actives can more readily reach and affect the muscle layer of the
area of application, e.g., face or neck, or the dermis layer of the skin,
where
sweat glands are located; e.g., underarm, foot; hand, etc. Compositions
comprising limonoid constituents, including liposome formulations, can also
be administered by direct injection subcutaneously or intradem~alty to more
precisely deposit the active agents at sites which require muscle relaxation
or decontraction via acetytcholine release inhibition.
[0046 Liposomes and delivery systems and vehicles involving
liposomes are welt-known in the art. tn brief, liposomes are untlamellar or
multifamellar lipid vesicles which entrap a significant fraction of aqueous
CA 02552442 2003-12-17
-21 -
solution. The vesicular microreservoirs of liposomes can contain a variety of
water-soluble materials, which are suspended within the emulsion (e.g.,
reviewed in G. Gregorius (Ed.), 1991, Liposome Technology, Vols. 1, II, Ill,
CRC Press, Boca Raton, Florida; Davis S.S. and Walker LM., 1987,
Methods in Enzymoiogy, 149:51-64; Mayhew E. et al., 1987, Mefhods in
Enzymoiogy, 149:64-77; and Shafer Korting M. et al., 1989, J. Am. Acad.
Dermatol_, 21:1271-1275). The preparation of liposomes and the variety of
uses of fiposomes in biological systems have been described (e.g., in U.S.
Patent No. 4,708,861 to M.C. Popescu et al., U.S. Patent No. 4,224,179 to
M. Schneider and U.S. Patent No. 4,235,871 to D.P. Papahadjopoulos et
ai.). Accordingly, such liposomes can be formulated into any of the
dermatological or cosmetic compositions as described herein.
[0047) In addition to the limonoid constituents as active agents, as
described herein, the physiotogically acceptable and pharmaceutical
compositions can contain suitable pharmaceutically acceptable carriers,
diluents, or excipients comprising auxiliaries which facilitate processing of
the active compounds into preparations which can be used
pharmaceutically. Further details on techniques for formulation and
administration are provided in the latest edition of Remington's
Pharmaceutical Sciences (Mack Publishing Co.; Easton, PA).
Pharmaceutical compositions containing the limonoid ingredients of the
present invention can be manufactured in a manner that is known in the art,
e.g., by means of conventional mixing, dissolving, granulating, dragee-
making, Ievigating, emulsifying, encapsulating, entrapping, or lyophilizing
processes.
[0048 If applicable, the pharmaceutical composition can be provided
as a salt and can be formed with many acids, including but not limited to,
hydrochloric, sulfuric, acetic, lactic, tartaric, malic, succinic, and the
like.
Salts tend to be more soluble in aqueous solvents, or other protonic
CA 02552442 2003-12-17
solvents, than are the corresponding free base forms. In other cases, the
preparation can be a lyophilized powder.
[0049] A preferred embodiment of the topical compositions of the
present invention also includes at feast one of the following: a surface
smoother, a skin plumper, an optical d'~ffuser, a sunscreen, an exfoliation
promoter, or an antioxidant.
[0050] A surface smoother provides the functional benefits of
enhancing skin smoothness and reducing the appearance of fine lines and
coarse wrinkles. F~camples include, without limitation, isopropyl myristate,
petrolatum, isopropyl lanolate, silicones (e.g., methicone, dimethicone), or
any mixtures thereof. The surface smoother is preferably present from
about 0.1 wt% to about 50 wt% of the total weight of the composition. A skin
plumper serves as a collagen enhancer to the skin. An example of a
suitable and preferred skin plumper is patmitoyt otigopeptide. Other
nontimiting examples of skirt piumpers include collagen andlor
glycosaminogtycan (GAG) enhancing agents. The skin plurhper is
preferably present from about 0.1 wt% to about 20 wt% of the total weight of
the composition.
[005] An optical diffuser is a particle that changes the surFace
optometrics of skin, resulting in a visual blurring and softening of, for
example, lines and wrinkles. Examples of optical diffusers that can be used
in the present invention include, but are not limited to, boron nitride, mica,
nylon, potymethytmethacrytate (PNiMA), polyurethane powder, sericite,
silica, silicone powder, talc, Tetfon~, titanium dioxide, zinc oxide, or any
mixtures thereof. The optical diffuser is preferably present from about 0.01
wt% to about 20 wt% of the total weight of the composition.
[0052 In another embodiment, the present invention embraces a
sunscreen that protects skin from damaging ultraviolet rays. Illustratively,
the sunscreen provides both UVA and UVB protection by using either a
CA 02552442 2003-12-17
-23-
single sunscreen or a combination of sunscreens. Among the sunscreens
that can be employed in the present compositions are avobenzone,
cinnamic acid derivatives (such as octylmethoxy cinnamate), octyt salicylate,
oxybenzone, ~tanium dioxide, zinc oxide, or any mixture or combination
thereof. Preferably, the sunscreen is present from about 1 wt% to about 30
wt% of the total weight of the composfion. In particular, the addition of a
sunscreen is preferred to prevent/reduce the photodegradation of the
composition andlor ingredients therein white in the package andlor on the
skin after application.
[0053 tt wilt be appreciated that the compositions of the present
invention containing sunscreen bring about additional improvements to the
aesthetic appearance of skin, including at least one of the following:
minimizes sunbuming, minimizes tanning, reduces redness, and reduces
future wrinkle development. It will be appreciated that when the topical
composition is intended to be applied prior to retiring for the evening, the
addition of a sunscreen agent may not be preferred.
[0054] The present compositions may also have one or more
exfoliation promoters. Suitable examples of an exfoliation promoter that can
be used in the present compositions inGude keratolytic agents, i.e., an
active agent having desquamating, exfotianf, or scrubbing properties; or an
active agent which can soften the homy layer of the sidn; alpha (a) and/or
beta (~i) hydroxy acids; benzoyl peroxide; keto acids, such as pyruvic acid,
2-oxopropanoic acid, 2-oxobutanoic acid, and 2-oxopentanoic acid; oxa
acids, as disclosed in U.S. Patent Nos. 5,847,003 and 5,834,513;
urea; rettnoids, or
any mixtures thereof. These anti-wrinkle or anti-fine line active agents can
be formulated, for example, in amounts of from about 0.0001 % to 5% by
weight relative to the total weight of the composition.
[0055] More specifically, examples of hydroxy acids include, but are
CA 02552442 2003-12-17
-24-
not limited to, a-hydroxy acids or ~-hydroxy acids, either linear, branched,
cyclic, saturated or unsaturated. The hydrogen atoms in the carbon-based
backbone of these materials can be substituted with halogens, halogen-
containing alkyl, acyl, acyloxy, alkoxycarbonyl, or alkoxy radicals having
from 2 to 18 carbon atoms. Suitable hydroxy acids include, for example,
glycolic acid, lactic acid, malic acid, tartaric acid, citric acid, 2-
hydroxyalkanoic acid, mandelic acid, salicylic acid and alkyl derivatives
thereof, including 5-n-octanoylsalicylic acid, 5-n-dodecanoytsalicyfic acid, 5-
n-decanoylsalicylic acid, 5-n-octylsalicylic acid, 5-n-heptyloxysalicylic
acid,
4-n-heptyloxysaiicylic acid and 2-hydroxy-3-methylbenzoic acid or atkoxy
derivatives thereof, such as 2-hydroxy-3-methyoxybenzoic acid. Exemplary
retinoids include, without limitation, retinoic acid (e.g., all-trans or 13-
cis) and
derivatives thereof, retinot (~tamin A) and esters thereof, such as retinol
palmitate, retinol acetate and retinol propionate, and salts thereof.
Preferred
exfoliation promoters are 3,6,9-trioxaundecanedioic aad, gtycotic acid, lactic
acid, or any mixtures thereof Other acids, such as oxa acid (e.g., U.S.
Patent No. 6,069,169) and an oxa diacid (e.g., U.S. Patent No. 5,932,229)
can be included in the compositions of this invention.
[0056] When the present invention includes an exfoliation promoter,
the composition typically includes about 0.5 wt% to 30 wt°~, preferably
about
1 wt% to about 15 wt%, more preferably about 2 wt% to about 10 wt%, and
most preferably about 4 wt%, of the exfoliation promoter based on the total
weight of the composition.
[007] An antioxidant functions, among other things, to scavenge free
radicals from skin to protect the skin from environmental agressors.
Examples of antioxidants that can be used in the present compositions
include compounds having phenalic hydroxy functions, such as ascorbic
acid and its derivatives/esters; beta-carotene; catechins; curcumin; ferufic
aad derivatives (e.g., ethyl fcrulate or sodium ferutate); Baltic acid
CA 02552442 2003-12-17
-25-
derivatives (e.g., propyt gatlate); lycopene; reductic acid; rosmarinic acid;
tannic acid; tetrahydrocurcumin; tocopherol and its derivatives; uric acid; or
any mixtures thereof. Other suitable antioxidants are those having one or
more thiol (-SH) functions, in either reduced or non-reduced form, such as
glutathione, lipoic acid, thioglycolic acid, and other sulfhydryl compounds.
The antioxidant may be inorganic, such as bisuffites, metabisutfites,
sulfites,
or.other inorganic salts and acids containing sulfur. Compositions of the
present invention can include an antioxidant preferably from about 0.001
wt% to about 10 wt%, and more preferably from about 0.001 wt% to about 5
wt%, of the total weight of the composition.
[0058] The compositions of this invention can also include one or
more of the following ingredients, additives, or adjuvants: anesthetics, anti-
altergenics, anti-fungals, antiseptics, chelating agents, coEorants,
dyestuffs,
demulcents, emollients, emulsifiers, fragrances, fitters, humectants,
lubricants, moisturizers, pH adjusters, pigment altering agents,
preservatives, skin penetration enhancers, stabilizers, surfactants,
thickeners, viscosity modifiers, hydrophilic or lipophilic getting agents,
vitamins, or any mixtures thereof: The amounts of these various
ingredients, additives, adjuuants, or active agents are those that are
conventionally used in the cosmetic or pham~aceuticat fields, for example,
they can constitute from about 0.01 % to 20% of the total weight of the
composition. In addition, the adjuvants, ingredients, additives, or active
agents can be introduced into the fatty phase, into the liquid phase, and/or
into lipid vesicles, depending on their nature.
[0059] The components) of the present invention are preferably
contained in a cosmetically acceptable medium (i.e., vehicle, diluent or
carrier). In an embodiment embracing topical application, the compositions
of this invention comprise a medium that is compatible with human skin.
The compositions can be formulated as aqueous, alcohol, or
CA 02552442 2003-12-17
-26-
aqueous/alcohol-based solutions, ointments, lotions, gels, water-in-oil, oil-
in-
water, or water-oil-water triple emulsions having the appearance of a cream
or gel, microemulsions, or aerosols. (n addition, the compositions can be in
the form of vesicular dispersions containing ionic and/or nonionic lipids, as
described above. Dosage units suitable for such pharmaceutical
compositions are formulated according to the conventional knowledge and
techniques used in the art.
j0060] More particularly, the compositions for topical application can
be in the form of a protective care composition for the skin, preferably for
the
face, the neck, the hands, the feet, or other areas of the body. Nonlimiting
examples indude day creams or lotions, night creams or lotions, sunscreen
creams, lotions, or oils, body milks, makeup (a foundation), artfidal tanning
compositions and depilatories.
[0061 ] If the composition of the invention is an emulsion, the
proportion of fatty substances comprised therein can range from about 5%
to 80%, by weight; preferably from about 5% to 50% by weight, reia6ve to
the total weight of the composition. The fatty substances and emulsifiers
used in the composition in emulsion form are one or more of those
conventionally employed in the cosmetic or pharmaceutical field.
Nontimiting examples of fatty substances include mineral oils (e.g.,
petroleum jelly), plant oils and hydrogenated derivatives thereof, animal
oils,
synthetic oils (e.g., perhydrosqualene), silicone oils (e.g.,
polydimethylsiloxane) and fluoro oils. Other exemplary fatty substances
include fatty alcohols (e.g., stearyl or cetyl alcohol), fatty adds (e.g.,
steam
acid} and waxes.
[0062] Emulsifiers are typically present in the compositions.of the
invention in an amount of about 0.3% to 30%, by weight and preferably from
about 0.5% to 30% by weight relative to the tots( weight of the composition.
X0063] In one embodiment, the present invention relates to the
CA 02552442 2003-12-17
-27-
administration of an effective amount of at least one limonoid constituent or
composition comprised thereof to inhibit or block acetylcholine release by
nerve cells at the NMJ to relax and/or decontract subcutaneous muscles,
particularly facial expression muscles, thereby smoothing out or unwrinkling
skin, wherein the inhibition of acefylcholine release by nerve cells at the
NMJ corresponds to muscle, preferably facial expression muscle relaxation
or decontraction.
[00643 In another embodiment, the present invention encompasses a
method of treating fine Lines, wrinkles, and/or other dermatological effects
of
. aging or photoexposure of skin, comprising applying to skin a composition
containing a limonoid in a cosmetically and/or dermatofogically acceptable
medium, and in an amount effective to treat, reduce, prevent and/or
ameliorate fine lines, wrinkles andlor other dermatotogical effects of aging
of
skin. In the method the limonoid is preferably a member of the family
Maliaecae, more preferably the limonoid is a plant alkaloid; most preferably
toosendanin, azadirachtin, or a combination thereof. The application of. the
limonoid containing composition is preferably topical. In addition, the
composition is preferably applied via a directed mode of delivery, for
example, by topical applicatiorf of an aqueous composition or transdermal
patch.
[0065) In yet another embodiment, the present invention
encompasses a method of treating hyperhidrosis or perspiration, comprising
applying to skin a composition containing a iimonoid in a cosmetically and/or
demzatologicaily acceptable medium, and in an amount effective to treat,
reduce, prevent and/or ameliorate hyperhidrosis or perspiration. in the
method the limonoid is preferably a member of the familyMaiiaecae, more
preferably the limonoid is a plant alkaloid, most preferably toosendanin,
azadirachtin, or a combination thereof. The application of the limonoid
containing composition is preferably topical.
CA 02552442 2003-12-17
-28-
[0066] Another embodiment of the present invention relates to a
method of improving the aesthetic appearance of skin and comprises
applying to the skin, or introducing viv a directed mode of delivery, a
composition including one or more limonoid constituents in an amount
effective to improve the aesthetic appearance of the skin. According to this
embodiment, the improvement in aesthetic appearance involves the
treatment of at least one condition, such as signs of dermatological aging.
Dermatologicat aging can include chronological aging, actinic aging,
hormonal aging, or any combination thereof.
[0067 As will be appreciated by the practitioner, cosmetic treatments
comprising compositions containing the limonoid constituents of the
invention can be carried out, for example, by topically applying the cosmetic
composition as described herein according to the routine technique for
administering such compositions. Routine and commonly practiced
techniques encompass the application of creams, lotions, gels, sera,
ointments, antiperspirants, or deodorants to the skin; spraying as a form of
application is also envisioned.
EXAMPLES
[0068] The following examples describe specific aspects of the
invention to illustrate the invention and provide a description of the present
methods for those of skit) in the art. The examples should not be construed
as limiting the invention, as the examples merely provide specific
methodology useful in the understanding and practice of the invention and
its 'various aspects.
Example 1
[00691 The plant alkaloids of the present invention can be extracted
from natural raw materials by using the methods of organic solvent
extraction or aqueous-organic solvent extraction, such as described in U.S.
CA 02552442 2003-12-17
_29_
Patent No. 6,372,239 to Wu et al., the contents of which are as set forth
below.
[0070 Seed cell culture: Plant seed cells are extracted principally
from the tissue of the embryo. The seed cell is then cultured. The total
seed cell is then broken down through breaking or fracturing of cell watts to
deliver the broad range of the plant cell constituents. Seed cell ccrltur~ are
further disclosed in commonly owned patent application U.S. publication
number 2003-0091659.
. [0071 J Oraanic solvent extraction The organic extraction method
involves a step of continuous washing and extracting the plant material
against a stream of organic solvent. F~camptes of organic solvents indude,
but are not limited to methanol, ethanol, dichloromethane, chloroform,
xylene, and petroleum ether. For example; organic solvent exbWon can
be conducted in an extracting machine. Raw materials collected from the
plant which contains the desired alkaloid(s), such as leaves, bark, seeds,
fivits, and/or roots, are first ground to smaN particle sizes, and then
put'into
the extracting machine through an inlet for the raw materials by a
measurable charging machine. The plant materials are pushed by a thruster
in the extracting machine and move forward slowly. Organic solvent (e:g:,
ethanol) is added into the machine through a solvent inlet at the top of a
waste discharging outlet. Due to the difference of gravity and equilibrium,
the solvent flows toward the raw material inlet, soaks the materials and flows
out from the opposite side of the solvent inlet. Since the plant materials and
the. solvent move in opposite directions against each other, the plant
materials are constantly immersed in a solution that contains tov~
concentration of extracted alkaloid(s). As a result of equilibrium, high yield
of plant alkatoid(s) can be achieved by continuously extracting the plant
material against the tow-concentration solution.
E0072J The time of extraction is preferably between about 1.-8 hours,
CA 02552442 2003-12-17
-30-
more preferably between about 2-6 hours, and most preferably between
about 3-5 hours. The temperature of extraction is preferably between about
30-90°C, more preferably befinreen about 40-70°C, and most
preferably
between about 50-60°C. The collected extract is then fine-filtered to
remove
debris, and concentrated by distilling the solvent until the solid content
reaches between about 25% and 45%. The distilled solvent can be reused
for extraction.
[0073] Aqueous-organic solvent extraction Raw materials collected
from a plant which contains the desired alkaloid(s), such as leaves, bark,
seeds, and/or roots of the plant, are first ground to small particle sizes.
The
ground plant material is soaked in aqueous solution that is acidic or
alkaline,
depending on the solubility and stability of the desire alkaloids) under
acidic
or alkaline (basic) conditions. For extraction under acidic conditions, an
acid
such as hydrochloric acid or sulfuric acid is added to water at concentration
of about 3% (w/v). For extraction under alkaline conditions, an alkali such
as sodium hydroxide or sodium carbonate is added to water.
[0074] The time of extraction is preferably between about 1-8 hours,
more preferably between about 2-6 hours, and most preferably between
about 3-5 hours. The temperature of extraction is preferably between about
30-90°C, more preferably between about 40-70°C, and most
preferably
befinreen about 50-60°C. The extract is then collected and fine-
filtered to
remove debris. Alkaline agents (e.g., ammonia) or acidifying agents (e.g.,
sulfuric acid) can be added to the extract to neutralize the solution by
adjusting the pH, depending on the acidity or alkalinity of the collected
extract. Organic solvent is then added to the neutralized solution to extract
the alkaloid from aqueous phase to organic phase. F~camples of such
organic solvents include, but are not limited to, butanot, pentanot, hexanol
and xytene. The extracted alkaloids) dissolved in organic solvent is/are
concentrated unfit the solid content reaches about 50-80%.
CA 02552442 2003-12-17
-31-
j0075J It should be noted that different plants containing different
kinds of alkaloids can be mixed and extracted together. This process of
mixed extraction can preferably be used for extracting those plants
containing alkaloids with similar solubility in the solvent used for
extraction,
such as ethanol. The mixture of alkaloids extracted can be concentrated
and stored in an appropriate solvent.
j0076j Toosendanin has a molea~tar weight of 574.60, is colorless
crystal, dissolves in methanol, chloroform and petroleum ether, and has a
melting. point of 244-245°C. For the extraction of toosendanin from
Melia
toosendan Sieb. et Zucc., dried seeds from Melia toosendan Sieb. et Zucc.
can be ground and extracted against methanot_ After fine-filtrafion and
concentration, the extract containing toosendanin is transferred into
turpentine and stored in a coot, dark place. The content of foosendanin is
fypicatty on the order of 20% by this procedure.
j007Tj Methods for extracting azadirachtin from plant materials, e.g.,
neem seeds, are described in H1, 541 to K.S. Holta.
j0078j Plant extracts for obtaining limonoids for use acco~ng to the
present invention are commerciaNy available. For example; Ku taan Pi
extract (containing toosendanin) is available from Premier Speddltres tnc.,
Middlesex, NJ. Ku Lian Pi is the Chinese name of the bark and root cortex
of MeGa toosendan Sieb. et Zucc., or M. azedarach L.; this material can also
be called Cortex Meliae. In addition; neem seed cell broth is available from
Phyton, tnc. Ithaca, NY. Neem extract is available from Carlisle
International Corp. NY.
Example 2
Clinic~evaluation of cosmefic~contraining limonoids
j0079] The safety arid efficacy of a topically administered composition
CA 02552442 2003-12-17
- 32 -
containing one or more limonoid constituents, e.g., toosendanin or
azadirachtin, is studied in human subjects after a single-dose administration
of a cosmetic formulation comprising the composition. Ten to fifteen
panelists (preferably between 35 and 50 years old) with mild to moderate
forehead lines and wrinkles are selected. The test subjects initially have a
skin replicate made to establish a baseline depth and severity of wrinkles.
[0080] Dermatotogical tests are known in the art for testing the
efficacy of an anti-wrinkling imposition. Any such test would be useful for
the present invention. For example, a layer of a flexible "non-cured"
material, such as latex, may be applied to the skin. Upon removal of the
"~~u material from the skin, the side that was adjacent to the skin can be
assessed, either visually or via instrumentation, to determine the extent of
wrinkling before treatment The same area of skin may then be assessed
after treatment to determine if there has been a change in number or depth
of wrinkles.
[008'1 ] On the following day, study ted~nicians apply 0:6 grams of
product (at a concentration of timonoid constituent of 140 mg/g) over an
approximate 6 cm2 semi-occlusive patch area on the subjects' foreheads.
The product formulation preferably consists of a formulation designed to
increase the penetrafion of water-soluble materials. The product remains on
the subjects' skin for one hour. After the one hour exposure, a repeat stun
replicate is taken to assess changes from the previous day. In addition, the
subjects are asked to actively contract the forehead skin and brow to
determine the overall efficacy and potency of the formulation.
am le 3
[0082] A composition comprising limonoid constituents according to
the present invention is prepared to assess its effects on one or more
derrnatofogical related skin conditions. The composition is in the form of an
oil-and=water emulsion and comprises the following ingredients:
CA 02552442 2003-12-17
-33-
Table 1
Oil-in-Water Emulsion
In redient Amount
Humectant e. . I cots, 1 0.5-15%
cerols
Thickeners (e.g. gums, starches,0.1-4%
t mers
Chelants t 0.001-0.5%
(e.g. disodium EDTA; tetrasodium
EDTA
Preservatives 0.01-2%
Sunscreen (e.g., benzophenone,0.1-50%
eth the Imetho cinnamate
Silicone 0.1-15%
Silica 0.01-1 p%
Fatty Alcohol/ Emulsifers 0.5-15%
/Wax/Fatty
Aad
Emoilienfs 0.1-20%
Extracts for limonoid constituents0.0001-50%
(e.g., one or more of Neem
seed cell
broth, Ku Lian Pi extract,
Neem extract
or an combination
Demineralized water ' Q.S.
Example 4
[0083] A composition comprising limonoid constituents according to
the presenfi invention is prepared to assess its effects on one or more
dermatological related skin conditions. The composition is in the form of an
oil-and-water emulsion and comprises the following ingredients:
Table 2
Oit-in-Water Emulsion
In redient Amount
Humectant e. ., I cots, 0.5-15%
( cerols
Thickeners (e.g. gums, starches, 0.1-4%
of mers
Chelants I 0.001-0.5%
e. . disodium EDTA~ tetrasodium
CA 02552442 2003-12-17
-34-
EDTA
Preservatives 0.01-2%
Sunscreen (e.g. Parsol~ 1789;0.1-50%
ethylhexylmethoxycinnamate;
benzo henone-3
Silicone 0.1-15%
Silica 0.01-10%
Fatty Alcohol/ Emulsifers 0.5-15%
/Vllax/Fatty
Acid (e.g., ceteth-20 phosphate/cetearyl
alcohol/dicetyl phosphate,
Tribehenin
PEG-20 Ester, Sodium Dihydroxycethyl
phosphate, cetearyl glucoside,
co ceride
Emulsion Stabilizers~scosityO.t-20%
Modfiers
(e.g., acryiateslC~o~o altcyl
acrylate
crosspolymer,
AcrylatelAminoacrylates/C~o-~
alkyl
PEG-20 ttaconate, Sodium
AcrylatelAcryloytdimethyt
Taurate
Coploymer, Acrylates/Ga3o
attcyl
a to cross mer
Film Formers (e.g. decene/butene0.001-2%
copolymer, acrytates/octylaaytamide
copolymer, adipic acidldiethylene
cot/ cerin cross 1 mer
Emollients 0.1-20%
Neem seed cell broth 0.01-10%
Neem extract U_01-10~
Ku Lian Pi exfract 0.01-10~
Demineralized water Q.S.
Example 5
[0084] A composition comprising limonoid constituents according to
the present invention is prepared to assess its effects on one or more
dermatological related skin conditions. 'Fhe composition is in the fom~ of a
water/silicone emulsion and comprises the following ingredients:
CA 02552442 2003-12-17
-35-
Tab 3
Water/Siticone Emulsion
M radiant Amount
Sodium PCA 50% 0.1-4%
Sodium Lactate 60% 0.01-10%
Sodium Chloride 0.1-10%
Humectant (e.g., glycerin, 0.5-10%
glyools,
1 carols
Ammonium h droxide 0.01-10%
C clomethicon 0.1-20%
C ctomethicone/Dimethicone 0.1-20%
Co ! Col
Emollients e. ., ce octanoate0.1 20%
Dimethicone Copolyoll 0.1-10%
C clo entasitoxane
Neem seed cell broth 0.01-10%
Neem extract 0_01-10%
Ku Lian Pi extract 0.01-1090
Demineralized water Q.S.
Example 6
j0085~ A composition comprising limonoid constituents according_to
the present invention is prepared to assess, its effects on one or more
dennatological related skin conditions. The composition is in the form of a
gel and comprises the following ingredients.
CA 02552442 2003-12-17
- 36--
Tabte 4
el
~edien Amount .
t
in
_ 0.01-3%
_
Carbo of
GI cerin 0.1-30%
B ene col 0.1-30%
Disodium EDTA 0.01-2%
Meth t araben 0.01 2%
dro eth ! ce!!ulose 0.01-2%
Com Zea ma s starch 0.01-10%
C.S. D&C Yetfow No.10 0.001-1 ~o
C.S. FD&C Blue No. 1 0.001-1
POE 20M meth i lucose ether0.01-10%
Dimeth I itoxane 0.01-10%
PEG 50 Shea butter 0.01-10%
Sodium h roxide solution 0.01-5~6
Ben alcohol 0.01-5~
Neem seed cell broth 0.01-10~
Neem extract 0.01-10%
Ku Van Pi extract 0.01-10%
Demineratized water [ Q.S.
Example 7
[0086] A composition comprising limonoid constituents according to
the present invention is prepared to assess its effects on one or more
dermatological related skin conditions. The composition is in the form of a
cleansing foam and comprises the following ingredients:
CA 02552442 2003-12-17
-37-
Table 5
~leansin. Fg oam
In redient Amount
Humectant (e.g., glycerin, butylene5-25%
I cot
Pot eth lene l cot 0.1-20%
Bentonite 0.1-20%
Stearic acid 0.1-30%
_ _ 0.1-20%
M risitc acid
Cetea ! AlcohotlCeteareth-20 1.00000%
Potassium h droxide 45% 0.1 20%
Preservatives (e.g., Benzyl 0.1-10%
alcohol, 2- _
Pheno ethanol
Neem seed cell broth 0.01-10%
Neem extract 0.01-10~
Ku dart Pi extract 0:09-10%
Demi~eratized water Q.S.
Example 8
[0087] A iiposome composition comprising tirt~onoid constituents
according to the present invention is prepared as fotiows:
abe6
i-i osome
In ~edierEt Amount
Lecicthir~ 5-25~
Ct _,s a# i benzoate '!-95%
Quatemium 15 Q_01:-2%
Parabens 0.01-2%
Neem seed ceii broth 0.09-10~
teem extract 0.01-10%
' Ku Lian Pi extract 0.01-10~
[0 0 8 8j The contents of all patents, patent applications, published
articles, at~stract's, boots, rei'erence manuals and abstracts, as cited
herein
are to more fully describe
CA 02552442 2003-12-17
-38-
the state of the art to which the invention pertains.
[0089j As various changes can be made in the above-described
subject matter without departing from the scope and spirit of the present
invention, it is intended that all subject matter contained in the above
description, or defined in the appended claims, be interpreted as descriptive
and illustrative of the present invention. Many modifications and variations
of the present invention are possible in light of the above teachings.
